SG Americas Securities’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $49.4M | Sell |
605,581
-274,120
| -31% | -$19.8M | 0.03% | 354 |
|
|
2026
Q1 | $59.9M | Sell |
879,701
-14,760
| -2% | -$1.05M | 0.06% | 244 |
|
|
2025
Q4 | $67.9M | Buy |
894,461
+764,364
| +588% | +$55.5M | 0.09% | 176 |
|
|
2025
Q3 | $7.98M | Buy |
130,097
+125,417
| +2,680% | +$6.53M | 0.03% | 372 |
|
|
2025
Q2 | $229K | Sell |
4,680
-507
| -10% | -$24.1K | ﹤0.01% | 2178 |
|
|
2025
Q1 | $264K | Buy |
+5,187
| New | +$259K | ﹤0.01% | 2321 |
|
|
2024
Q4 | – | Sell |
-22,514
| Closed | -$835K | – | 3522 |
|
|
2024
Q3 | $835K | Buy |
+22,514
| New | +$754K | ﹤0.01% | 1223 |
|
|
2023
Q4 | – | Sell |
-42,949
| Closed | -$962K | – | 3376 |
|
|
2023
Q3 | $962K | Buy |
42,949
+21,173
| +97% | +$787K | 0.01% | 1300 |
|
|
2023
Q2 | $886K | Sell |
21,776
-4,652
| -18% | -$228K | 0.01% | 1108 |
|
|
2023
Q1 | $1.28M | Buy |
26,428
+22,210
| +527% | +$1.02M | 0.01% | 966 |
|
|
2022
Q4 | $161K | Buy |
+4,218
| New | +$175K | ﹤0.01% | 2372 |
|
|
2022
Q3 | – | Sell |
-12,214
| Closed | -$489K | – | 3476 |
|
|
2022
Q2 | $489K | Buy |
12,214
+6,897
| +130% | +$242K | 0.01% | 1981 |
|
|
2022
Q1 | $198K | Sell |
5,317
-10,138
| -66% | -$391K | ﹤0.01% | 2440 |
|
|
2021
Q4 | $616K | Sell |
15,455
-20,972
| -58% | -$803K | ﹤0.01% | 2014 |
|
|
2021
Q3 | $1.35M | Buy |
36,427
+33,723
| +1,247% | +$1.39M | 0.01% | 1643 |
|
|
2021
Q2 | $114K | Sell |
2,704
-18,465
| -87% | -$791K | ﹤0.01% | 2589 |
|
|
2021
Q1 | $1M | Buy |
21,169
+18,367
| +655% | +$1.09M | 0.01% | 1540 |
|
|
2020
Q4 | $171K | Sell |
2,802
-12,686
| -82% | -$748K | ﹤0.01% | 2719 |
|
|
2020
Q3 | $724K | Buy |
15,488
+11,040
| +248% | +$544K | ﹤0.01% | 1395 |
|
|
2020
Q2 | $226K | Sell |
4,448
-17,607
| -80% | -$865K | ﹤0.01% | 2758 |
|
|
2020
Q1 | $984K | Buy |
22,055
+13,531
| +159% | +$681K | 0.01% | 1300 |
|
|
2019
Q4 | $409K | Buy |
+8,524
| New | +$362K | ﹤0.01% | 1941 |
|
|
2019
Q3 | – | Sell |
-2,840
| Closed | -$128K | – | 3172 |
|
|
2019
Q2 | $128K | Sell |
2,840
-4,374
| -61% | -$173K | ﹤0.01% | 2678 |
|
|
2019
Q1 | $272K | Buy |
+7,214
| New | +$242K | ﹤0.01% | 2342 |
|
|
2018
Q3 | – | Sell |
-8,415
| Closed | -$284K | – | 3402 |
|
|
2018
Q2 | $284K | Buy |
+8,415
| New | +$262K | ﹤0.01% | 2383 |
|
|
2017
Q4 | – | Sell |
-41,694
| Closed | -$834K | – | 3533 |
|
|
2017
Q3 | $834K | Buy |
+41,694
| New | +$816K | 0.01% | 1402 |
|
|
2017
Q1 | – | Sell |
-21,435
| Closed | -$234K | – | 3515 |
|
|
2016
Q4 | $234K | Buy |
+21,435
| New | +$225K | ﹤0.01% | 2239 |
|
|
2015
Q4 | – | Sell |
-4,148
| Closed | -$111K | – | 2925 |
|
|
2015
Q3 | $111K | Buy |
4,148
+1,323
| +47% | +$56.6K | ﹤0.01% | 1805 |
|
|
2015
Q2 | $136K | Buy |
2,825
+139
| +5% | +$8.11K | ﹤0.01% | 2184 |
|
|
2015
Q1 | $163K | Sell |
2,686
-7,689
| -74% | -$469K | ﹤0.01% | 1992 |
|
|
2014
Q4 | $537K | Buy |
+10,375
| New | +$457K | ﹤0.01% | 1606 |
|
|
2013
Q4 | – | Sell |
-6,698
| Closed | -$144K | – | 2933 |
|
|
2013
Q3 | $144K | Buy |
+6,698
| New | +$116K | ﹤0.01% | 2411 |
|
Other funds holding PTCT
RI
JT
SG Americas Securities's PTCT Position: Q2 2026 in Review
SG Americas Securities reduced its PTC Therapeutics (PTCT) stake by 31% in Q2 2026, selling an estimated $19.8M and leaving 605,581 shares worth $49.4M. The position accounts for 0.03% of the portfolio, ranked #354.
SG Americas Securities first reported a position in PTCT in Q3 2013 and has held it in 32 quarters since. The position peaked at $67.9M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- SG Americas Securities held 605,581 shares of PTC Therapeutics worth $49.4M as of Q2 2026.
- SG Americas Securities sold 274,120 PTC Therapeutics shares in Q2 2026, an estimated $19.8M.
- PTC Therapeutics made up 0.03% of SG Americas Securities's portfolio in Q2 2026, its #354 holding.
- SG Americas Securities first reported a position in PTC Therapeutics in Q3 2013 and has held it in 32 quarters since.
- SG Americas Securities's PTC Therapeutics position peaked at $67.9M in Q4 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.